A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma

Official Title

A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)


Study consists of two parts, a part 1 dose escalation and a part 2 cohort expansion in combination with dexamethasone and carfilzomib intravenously across two cohorts with a monotherapy component as well.

Trial Description

Primary Outcome:

  • Part 1: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs)
  • Part 1 And 2: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) with adverse events leading to discontinuation, and AEs graded according NCI-CTCAE Version 5
  • Part 2: Overall response rate (ORR)
  • Part 2: Very good partial response (VGPR) or better response rate
  • Part 2: Complete Response (CR) or better
Secondary Outcome:
  • Part 1: Area under the plasma concentration-time curve (AUC)
  • Part 1: Maximum observed plasma concentration (Cmax)
  • Part 1: Time to reach Cmax (tmax)
  • Part 1: After steady-state: AUC last,ss
  • Part 1: After steady-state: Cmax, ss
  • Part 1: After steady-state: trough plasma concentration (Ctrough) ss
  • Part 1: After steady-state: time to reach Cmax (tmax,ss)
  • Part 2: Time to response (TTR) as assessed by investigator
  • Part 2: Duration of response (DOR) as assessed by investigator
  • Part 2: Progression-free survival (PFS) as assessed by investigator
  • Part 2: Overall survival (OS) as assessed by investigator

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society